Episode
Her Daughter’s Brain Tumor Turned Her Into a Biotech Founder | Tracy Ryan
- Podcast
- BioTalk Unzipped
- Published
- Jul 20, 2026
- Duration seconds
- 3858
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/biotalk-unzipped-6702602/episodes/her-daughter-s-brain-tumor-turned-her-into-a-biotech-founder-tracy-ryan/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/biotalk-unzipped-6702602/her-daughter-s-brain-tumor-turned-her-into-a-biotech-founder-tracy-ryan.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
A mother’s search for answers to her daughter’s relentless brain tumor led her into natural killer cell biology, cancer immunotherapy, and biotech entrepreneurship. Sponsored by Leucentra, https://leucentra.com/ Inspired by science, empowered by IT. Leucentra helps life science and healthcare organizations evaluate, implement, and get more value from technology that supports innovation. Tracy Ryan, co-founder of NKore BioTherapeutics and former chief communications officer, joins Gregory Austin and Dr. Chad Briscoe to explain how her daughter Sophie’s pediatric brain tumor transformed her from a parent searching for options into a cancer advocate, research fundraiser, and biotechnology founder. The conversation examines the scientific reasoning that moved Tracy from medical cannabis advocacy toward NK-cell immunotherapy. She describes an immune-system finding involving Sophie’s natural killer cells, the work of the late UCLA scientist Dr. Anahid Jewett, and the development of an experimental allogeneic NK-cell platform designed to enhance immune activity without genetic engineering. The episode also explores the practical realities of translating an early scientific hypothesis into a therapeutic program, including donor selection, cell persistence, manufacturing, treatment outside the United States, regulatory requirements, clinical evidence, and the difficulty of raising capital for an emerging cell-therapy company. At the center of the discussion is a difficult question: how do scientists, founders, regulators, and families preserve urgency when patients need better options, while still requiring the controlled evidence needed to determine whether a therapy is safe and effective? What you will learn: • How Sophie’s pediatric brain tumor changed the direction of Tracy…